Other adverse events included an increase in bilirubin in ten (16.0%) patients, aspartate aminotransferase (AST) rise > 3 times in seven (11.1%) patients and alanine aminotransferase (ALT) rise > 3 times in six (9.5%) patients, new onset or worsening of ascites in thirteen (20.6%) patients, and new onset HE in one (1.6%) patient. This evidence concerns the gene GPT and Ascites.